Shilpa Biologicals partners with mAbTree Biologics AG for a novel immunooncology asset
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
This e-commerce platform is launched as a hyperlocal model
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
There are 38.4 million people with diabetes in the United States
ANVIMO will be available in dosages of 240 mg and 480 mg
Nadda also commended the role of ASHA workers, “grassroot foot soldiers”, in the healthcare system
Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine
The approval marks Venus Remedies’ strategic entry into complex generics, expanding its injectable portfolio beyond traditional formulations
In financial year 2024-25, PMBJP has made sales of Rs. 1,760 crore (at MRP) till Feb 2025
Subscribe To Our Newsletter & Stay Updated